Febuxostat (CAS 144060-53-7): A Comprehensive Product Introduction
Febuxostat, with the CAS number 144060-53-7, is a remarkable pharmaceutical compound that has gained significant attention in the medical field. It is a potent and selective inhibitor of xanthine oxidase, which plays a crucial role in the production of uric acid. By inhibiting xanthine oxidase, Febuxostat effectively reduces the production of uric acid in the body, making it a valuable therapeutic agent for the treatment of hyperuricemia and gout.
Properties of Febuxostat
Febuxostat is a white to off – white crystalline powder. Its chemical formula is C16H16N2O3S, and it has a molecular weight of approximately 316.37 g/mol. It is sparingly soluble in water, slightly soluble in methanol, and soluble in dimethyl sulfoxide (DMSO). The melting point of Febuxostat ranges from 205 – 208 °C. These physical and chemical properties are important for its formulation into different pharmaceutical dosage forms.
Mechanism of Action
Xanthine oxidase is an enzyme involved in the metabolic pathway that converts hypoxanthine to xanthine and then to uric acid. Febuxostat binds to the molybdenum – pterin center of xanthine oxidase, thereby inhibiting its activity. This inhibition leads to a decrease in the production of uric acid, which helps to lower the serum uric acid levels in patients with hyperuricemia. Unlike allopurinol, another commonly used urate – lowering drug, Febuxostat is a non – purine inhibitor of xanthine oxidase, which may offer certain advantages in terms of efficacy and safety.
Medical Uses
Treatment of Gout
Gout is a form of arthritis caused by the deposition of urate crystals in the joints due to elevated serum uric acid levels. Febuxostat is indicated for the long – term management of hyperuricemia in patients with gout. Clinical studies have shown that Febuxostat can effectively lower serum uric acid levels to the target range (less than 6 mg/dL) in a significant proportion of patients. This reduction in uric acid levels helps to prevent the formation of new urate crystals, reduce the frequency and severity of gout attacks, and promote the dissolution of existing urate crystals in the joints.
Hyperuricemia Associated with Other Conditions
Hyperuricemia can also be associated with other medical conditions such as kidney disease, certain types of cancer (especially during chemotherapy), and metabolic syndrome. Febuxostat may be used in these cases to manage the elevated uric acid levels and prevent complications related to hyperuricemia, such as urate nephropathy and acute kidney injury.
Advantages over Traditional Therapies
Compared to allopurinol, Febuxostat has several advantages. Allopurinol is a purine – based inhibitor of xanthine oxidase, and some patients may experience hypersensitivity reactions, which can range from mild skin rashes to severe and life – threatening conditions such as Stevens – Johnson syndrome. Febuxostat, being a non – purine inhibitor, has a lower risk of such hypersensitivity reactions. Additionally, Febuxostat may be more effective in lowering uric acid levels, especially in patients who are poor responders to allopurinol.
Applications in Different Fields
Pharmaceutical Industry
In the pharmaceutical industry, Febuxostat is mainly used for the development of drugs for the treatment of hyperuricemia and gout. It is formulated into tablets of different strengths, such as 40 mg and 80 mg, for oral administration. The pharmaceutical companies conduct extensive research and development activities to optimize the formulation of Febuxostat products, improve their bioavailability, and ensure their quality and safety.
Medical Research
Febuxostat is also an important tool in medical research. Scientists use it to study the role of xanthine oxidase in various physiological and pathological processes. For example, research is being conducted to explore the potential of Febuxostat in the treatment of other diseases related to oxidative stress and inflammation, such as cardiovascular diseases and neurodegenerative diseases. The anti – oxidative and anti – inflammatory properties of Febuxostat, which are associated with its inhibition of xanthine oxidase, may have beneficial effects in these conditions.
Preparation Methods of Febuxostat
Chemical Synthesis Route 1
One common method for the synthesis of Febuxostat involves the reaction of 2 – (3 – cyano – 4 – isobutoxyphenyl) – 4 – methylthiazole – 5 – carboxylic acid with appropriate reagents. The starting material, 2 – (3 – cyano – 4 – isobutoxyphenyl) – 4 – methylthiazole – 5 – carboxylic acid, can be prepared through a series of reactions. First, 4 – isobutoxybenzonitrile is reacted with a suitable halogenating agent to introduce a halogen atom at the 3 – position. Then, this intermediate is reacted with a thiazole derivative to form the key intermediate. Finally, the carboxylic acid group is introduced through hydrolysis, and further purification steps are carried out to obtain pure Febuxostat.
Chemical Synthesis Route 2
Another synthesis route starts from 4 – isobutoxybenzaldehyde. It is first converted to 4 – isobutoxybenzyl bromide through bromination. Then, this compound is reacted with a thiazole – containing compound to form an intermediate. After a series of oxidation and substitution reactions, the cyano group and the carboxylic acid group are introduced step – by – step. The final product is obtained after purification by methods such as recrystallization or column chromatography.
Quality Control and Purity
To ensure the safety and efficacy of Febuxostat products, strict quality control measures are implemented during its production. The purity of Febuxostat is typically determined by high – performance liquid chromatography (HPLC). The impurities in Febuxostat are carefully monitored, and their levels are controlled within the acceptable limits specified by regulatory authorities. Other quality parameters such as particle size, dissolution rate, and stability are also evaluated to ensure the consistency and quality of the final pharmaceutical products.
Dosage and Administration
The recommended starting dose of Febuxostat for the treatment of hyperuricemia in patients with gout is usually 40 mg once daily. After 2 weeks of treatment, the serum uric acid level is measured. If the uric acid level is still above the target range, the dose can be increased to 80 mg once daily. Febuxostat should be taken orally, with or without food. It is important to note that patients should be well – hydrated during treatment to prevent the formation of urate stones in the kidneys.
Side Effects and Precautions
Like any other drug, Febuxostat may cause some side effects. The most common side effects include liver function abnormalities, nausea, diarrhea, and rash. In rare cases, more serious side effects such as severe liver injury, allergic reactions, and cardiovascular events may occur. Patients with a history of liver or kidney disease, heart disease, or other serious medical conditions should be closely monitored during treatment with Febuxostat. It is also important to inform the healthcare provider about all the medications, supplements, and herbal products that the patient is taking, as there may be potential drug interactions.
Send Inquiry